Although it seems that HDAC inhibitors show higher efficacy in hematological malignancies than in solid tumors, our finding of MYC being a primary target of panobinostat in addition to its anticipated general ability to inhibit HDAC function provides a valuable rationale to use this drug for the treatment of hepatoblastoma. Here, MYC is linked to hepatoblastoma.